Lung transplant rejection – Diagnostics – Overview of Information and Clinical Research

Understanding lung transplant rejection begins with recognizing that it is far more common than most people realize, affecting the majority of transplant recipients at some point. While hearing the word “rejection” can sound frightening, many forms are treatable with proper monitoring and quick medical response, making early detection through regular testing absolutely vital for long-term transplant success.

Introduction: Who Should Undergo Diagnostics

Anyone who receives a lung transplant needs to understand that regular diagnostic monitoring is not optional—it is a lifelong necessity. The immune system, which is your body’s natural defense against foreign invaders, sees the transplanted lung as something that doesn’t belong. This means that every lung transplant recipient will need ongoing testing to catch any signs of rejection early, when treatment is most effective.^[1]

Diagnostics for lung transplant rejection should begin immediately after surgery and continue throughout the recipient’s lifetime. In the first few weeks and months following transplantation, testing is frequent because the risk of acute rejection—rejection that happens suddenly—is highest during this time. Studies show that acute cellular rejection of lung transplants occurs in up to 90 percent of patients, though this doesn’t mean all cases are severe or require intensive treatment.^[3]

You should seek diagnostic testing immediately if you notice any warning signs between your scheduled appointments. Common symptoms that signal possible rejection include fever, chills, flu-like body aches, and increasing shortness of breath. These symptoms are similar to what you might experience with a common infection, which is exactly why proper testing is essential—you cannot tell the difference without medical evaluation.^[8]

The timing of diagnostics matters greatly because rejection can be categorized by when it occurs after transplant. Hyperacute rejection happens within the first 24 hours after surgery, acute rejection typically occurs within the first week to the first year, and chronic rejection, more properly called chronic lung allograft dysfunction or CLAD, develops after the first year and becomes increasingly common as time passes.^[2]

Patients who show any decline in lung function—even small changes—need diagnostic evaluation right away. The transplant team will send every lung transplant recipient home with a spirometry machine, which is a handheld device used to measure how much air you can exhale in one second. If this measurement drops by more than 10 percent from your baseline, you must contact your doctor for evaluation. This simple home monitoring tool often provides the first clue that rejection might be occurring.^[3]

⚠️ Important

Never ignore new symptoms or wait to see if they improve on their own. Rejection caught early is far more treatable than rejection that has progressed. Contact your transplant team immediately if you experience fever, increased shortness of breath, persistent cough, fatigue, or a drop in your home spirometry readings. Quick action can make the difference between simple outpatient treatment and hospitalization.

Diagnostic Methods for Identifying Rejection

Diagnosing lung transplant rejection requires multiple types of testing because no single test can give the complete picture. The diagnostic process typically begins with monitoring lung function and progresses to more detailed examinations when problems are suspected. Understanding these methods helps patients know what to expect and why each test matters.^[5]

Spirometry and Lung Function Monitoring

The first line of diagnostic monitoring involves measuring how well the transplanted lung is working. Every lung transplant recipient receives a spirometry device to use at home twice daily. This simple breathing test measures the volume of air you can forcefully exhale in one second, called FEV1 (forced expiratory volume in one second). Your transplant team establishes your personal best measurement after surgery, and this becomes your baseline for comparison.^[3]

When spirometry readings drop significantly—usually by 10 percent or more—this signals that something has changed in the lung. While a drop doesn’t automatically mean rejection is occurring, it serves as an alarm bell that triggers further diagnostic testing. The beauty of home spirometry is that it can detect problems before you feel sick, allowing for earlier intervention.^[3]

Lung Biopsy

A lung biopsy is considered the gold standard for diagnosing rejection because it allows doctors to examine lung tissue directly under a microscope. During this procedure, doctors insert a thin, flexible tube called a bronchoscope through your mouth or nose, down into your airways. Small samples of tissue from different areas of the lung are collected for examination.^[3]

The biopsy procedure is performed regularly in the first year after transplant, even when patients feel fine, because it can detect rejection before symptoms appear. Laboratory specialists examine the tissue samples looking for lymphocytes, which are a type of white blood cell. In rejection, these cells infiltrate the lung tissue and attack the blood vessels. The severity of rejection is graded on a scale from zero to four, with zero meaning no rejection and four representing the most severe rejection.^[3]

Lung biopsies are also crucial for distinguishing between rejection and infection, which can look very similar based on symptoms alone. This distinction matters tremendously because the treatments are completely different—rejection requires more immunosuppression to calm the immune system, while infection may require reducing immunosuppression and adding antibiotics or antiviral medications.^[5]

Blood Tests for Antibodies

Blood tests play an important role in detecting a specific type of rejection called antibody-mediated rejection (AMR). In this form of rejection, the recipient’s immune system produces antibodies—specialized proteins that target the donor lung’s tissues. These antibodies can be measured in the blood before they cause obvious symptoms or lung function decline.^[5]

Testing for donor-specific antibodies occurs on a regular schedule: monthly during the first year after transplant, every three months during the second year, and then annually thereafter. If antibodies begin to form, doctors can start treatment immediately, often preventing more serious rejection from developing. This preventive approach, using a therapy called plasma exchange where blood is filtered to remove harmful antibodies, has improved outcomes significantly.^[3]

Additional blood tests monitor general health and medication levels. Immunosuppressive drugs must be kept within a specific range—too little and rejection risk increases, too much and infection risk rises while side effects worsen. Regular blood draws check drug concentrations to ensure they remain in the therapeutic window.^[5]

Imaging Studies

Chest X-rays and CT scans (computed tomography scans) provide visual information about the lung’s structure and can reveal changes that suggest rejection or complications. A chest X-ray is quick and uses low-dose radiation to create images showing the lung’s general appearance, the position of airways, and any fluid accumulation. CT scans provide much more detailed three-dimensional images and can detect subtle changes in lung tissue that might not show up on regular X-rays.^[5]

These imaging tests are particularly valuable for identifying chronic rejection, which causes characteristic changes in lung architecture over time. In one form of chronic rejection called bronchiolitis obliterans syndrome (BOS), the small airways become narrowed and scarred. Another form called restrictive allograft syndrome (RAS) causes the lungs to become smaller and stiffer, making it progressively harder to breathe.^[3]

Physical Examination and Symptom Assessment

Never underestimate the importance of a thorough physical examination. During clinic visits, your transplant team will listen to your lungs with a stethoscope, check your oxygen levels using a small device called a pulse oximeter that clips onto your finger, measure your vital signs including temperature and blood pressure, and ask detailed questions about any symptoms you’re experiencing.^[8]

The six-minute walk test is another diagnostic tool that measures how far you can walk in six minutes while monitoring your oxygen levels. This test provides valuable information about your overall functional capacity and can detect gradual declines that might indicate developing problems. A shorter walking distance compared to previous tests, or a significant drop in oxygen levels during the walk, raises concerns that warrant further investigation.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments for lung transplant rejection require specific diagnostic criteria to ensure that participants truly have the condition being studied and to monitor how they respond to experimental therapies. These trials are crucial for advancing medical knowledge and developing better treatments for transplant recipients.^[13]

Entry into clinical trials typically requires documented evidence of rejection through lung biopsy showing specific grades of cellular rejection or presence of antibody-mediated rejection based on established criteria. The International Society for Heart and Lung Transplantation (ISHLT) has developed standardized classification systems that researchers use worldwide to ensure consistency in diagnosing and grading rejection.^[5]

For acute cellular rejection trials, biopsies must show at least a certain minimal grade of rejection according to the ISHLT classification system. This system examines two main features: perivascular inflammation (inflammation around blood vessels) and airway inflammation. Pathologists assign grades ranging from A0 to A4 for vascular rejection and B0 to B2R for airway rejection, with higher numbers indicating more severe rejection.^[5]

Chronic rejection trials, particularly those studying treatments for bronchiolitis obliterans syndrome, require documentation of persistent decline in lung function. Specifically, patients must show at least a 20 percent decline in FEV1 from their post-transplant baseline that persists for at least three months. Additional criteria might include CT scan findings consistent with chronic rejection or biopsy evidence when available, though biopsy of chronic rejection is notoriously difficult because the changes occur in small airways that are hard to sample.^[4]

Antibody-mediated rejection trials require the most complex diagnostic workup because this type of rejection demands multiple pieces of evidence. Diagnosis typically requires four components: evidence of antibodies against the donor’s tissue detected in blood tests, tissue biopsy showing specific changes under the microscope, special staining of biopsy tissue showing antibody deposits, and clinical or laboratory evidence of lung dysfunction. This multidisciplinary approach ensures accurate diagnosis before enrolling patients in studies.^[5]

All clinical trials require baseline testing before treatment begins and regular monitoring throughout the study period. This typically includes spirometry at every visit, regular lung biopsies (often every few months), chest imaging, blood tests for immunosuppressive drug levels and antibodies, and quality of life assessments. These frequent tests serve two purposes: monitoring patient safety and collecting data to determine whether the experimental treatment works.^[5]

Exclusion criteria are equally important for clinical trials. Patients with active infections, recent cancer, severe kidney or liver problems, or other major health issues may not qualify because these conditions could interfere with study results or put participants at unacceptable risk. Some trials exclude patients taking certain medications that might interact with the experimental treatment being tested.^[5]

⚠️ Important

Participating in a clinical trial means undergoing more frequent testing than standard care requires, but it also means receiving extremely close monitoring by experts. The additional tests and clinic visits can be burdensome, but they may catch problems earlier than routine surveillance would. Always discuss the testing schedule and time commitment with your transplant team before agreeing to participate in any clinical trial.

Prognosis and Survival Rate

Prognosis

The outlook for lung transplant recipients depends heavily on whether rejection can be controlled and what type of rejection develops. Acute cellular rejection, while common, generally has a good prognosis when detected early and treated appropriately. Up to 90 percent of lung transplant recipients experience at least one episode of acute rejection, yet many of these episodes respond well to treatment with increased immunosuppression, particularly corticosteroids. Patients can often be treated at home, and the rejection reverses without causing permanent damage to the lung.^[3]

The prognosis becomes more concerning when acute rejection episodes occur repeatedly or when treatment fails to reverse the rejection. These situations increase the risk of developing chronic rejection, which has a much more serious outlook. Chronic lung allograft dysfunction affects more than half of lung transplant recipients who survive beyond five years, and it remains the leading cause of death after the first year following transplantation.^[4]

Among the forms of chronic rejection, restrictive allograft syndrome carries a particularly poor prognosis compared to bronchiolitis obliterans syndrome. Patients with restrictive allograft syndrome experience more rapid decline in lung function and overall worse outcomes. Unfortunately, chronic rejections typically cannot be reversed once they develop, and treatment focuses on slowing progression rather than cure. When chronic rejection progresses despite all treatments, re-transplantation becomes the only remaining option, though not all patients are candidates for a second transplant.^[3]

Several factors influence an individual’s prognosis after diagnosis of rejection. Younger patients generally have better outcomes than older recipients. The specific underlying disease that led to transplant can also affect prognosis—for example, patients transplanted for cystic fibrosis often have different outcomes than those transplanted for pulmonary fibrosis. Medication compliance is absolutely critical; patients who miss doses of immunosuppressive medications face much higher rejection rates and worse outcomes. Other risk factors for poor prognosis include cytomegalovirus infection, gastroesophageal reflux disease, and previous episodes of acute rejection.^[2]

Survival Rate

Survival statistics for lung transplant recipients show improvement over time as surgical techniques and immunosuppressive medications advance, but lung transplantation still has lower survival rates compared to other solid organ transplants. The five-year survival rate for lung transplant recipients is reported at 58 percent, meaning that just over half of recipients are alive five years after their transplant. This represents a significant challenge compared to other organ transplants like kidney or liver, which have considerably higher five-year survival rates.^[2]

The first year after transplant represents a particularly vulnerable period. Within the first year, approximately 50 percent of recipients experience at least one episode of acute rejection. While most of these episodes are treatable, they increase the risk of later complications. Between 30 days and one year after transplant, graft failure—meaning the transplanted lung stops working—accounts for nearly 23 percent of deaths during this time period.^[5]

After surviving the first year, chronic lung allograft dysfunction becomes the primary threat to long-term survival. Studies show that approximately 45 percent of lung transplant recipients develop chronic rejection within five years after transplant. The median survival after diagnosis of chronic rejection varies depending on the specific type, but for bronchiolitis obliterans syndrome, patients typically experience progressive decline over several years. For restrictive allograft syndrome, decline tends to be more rapid, with median survival after diagnosis measured in months rather than years.^[2]

Recent advances offer hope for improved survival in the future. New immunosuppressive medications may prevent rejection more effectively with fewer side effects. Research into the cellular and molecular mechanisms driving chronic rejection has identified potential drug targets that could lead to better treatments. Some transplant centers report survival rates better than the national average, suggesting that specialized expertise and comprehensive care programs can improve outcomes. The development of better diagnostic tools that catch rejection earlier, combined with more effective treatments, continues to push survival rates upward year by year.^[7]

#1 Clinical Trials Search in Europe